PIACENTINI, Federico
PIACENTINI, Federico
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
2017 Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS
2010 Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V.
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS?
2012 Conte, P.; Verrusio, Manuela; Piacentini, F.
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
2018 Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R.
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study.
2018 Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
2017 Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
2008 Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
2009 Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
2017 Vici, P; Pizzuti, L; Michelotti, A; Sperduti, I; Natoli, C; Mentuccia, L; Di Lauro, L; Sergi, D; Marchetti, P; Santini, D; Magnolfi, E; Iezzi, L; Moscetti, L; Fabbri, A; Cassano, A; Grassadonia, A; Omarini, Claudia; Piacentini, Federico; Botticelli, A; Bertolini, I; Scinto, Af; Zampa, G; Mauri, M; D'Onofrio, L; Sini, V; Barba, M; Maugeri Saccà, M; Rossi, E; Landucci, E; Tomao, S; Alberti, Am; Giotta, F; Ficorella, C; Adamo, V; Russo, A; Lorusso, V; Cannita, K; Barni, S; Laudadio, L; Greco, F; Garrone, O; Giulia, Md; Marolla, P; Sanguineti, G; Di Cocco, B; Ciliberto, G; De Maria, R; Gamucci, T.
Abemaciclib: eventi avversi e riduzione di dose.
2021 Piacentini, F
Achievements and unmet needs in the management of advanced ovarian cancer
2010 Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER
2010 Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V.
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study
2021 Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V.
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting
2023 D'Onofrio, Raffaella; Omarini, Claudia; Toss, Angela; Sperduti, Isabella; Piacentini, Federico; Barbolini, Monica; Cortesi, Laura; Barbieri, Elena; Pettorelli, Elisa; Chiavelli, Chiara; Dominici, Massimo; Moscetti, Luca
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis
2021 D'Onofrio, R.; Piacentini, F.; Barbolini, M.; Isca, C.; Nasso, C.; Caggia, F.; Dominici, M.; Moscetti, L.; Omarini, C.
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
2015 Piacentini, Federico
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
2010 Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
2019 Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V.
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature
2022 Tornincasa, Antonio; Canino, Fabio; Trudu, Lucia; Barbolini, Monica; Moscetti, Luca; Omarini, Claudia; Dominici, Massimo; Piacentini, Federico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer | 1-gen-2017 | Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V | |
| 35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS | 1-gen-2010 | Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V. | |
| 41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? | 1-gen-2012 | Conte, P.; Verrusio, Manuela; Piacentini, F. | |
| 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio | 1-gen-2018 | Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R. | |
| 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. | 1-gen-2018 | Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina | |
| 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER | 1-gen-2017 | Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina | |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | 1-gen-2020 | Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P | |
| A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy | 1-gen-2008 | Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco | |
| A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. | 1-gen-2009 | Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco | |
| A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. | 1-gen-2017 | Vici, P; Pizzuti, L; Michelotti, A; Sperduti, I; Natoli, C; Mentuccia, L; Di Lauro, L; Sergi, D; Marchetti, P; Santini, D; Magnolfi, E; Iezzi, L; Moscetti, L; Fabbri, A; Cassano, A; Grassadonia, A; Omarini, Claudia; Piacentini, Federico; Botticelli, A; Bertolini, I; Scinto, Af; Zampa, G; Mauri, M; D'Onofrio, L; Sini, V; Barba, M; Maugeri Saccà, M; Rossi, E; Landucci, E; Tomao, S; Alberti, Am; Giotta, F; Ficorella, C; Adamo, V; Russo, A; Lorusso, V; Cannita, K; Barni, S; Laudadio, L; Greco, F; Garrone, O; Giulia, Md; Marolla, P; Sanguineti, G; Di Cocco, B; Ciliberto, G; De Maria, R; Gamucci, T. | |
| Abemaciclib: eventi avversi e riduzione di dose. | 1-gen-2021 | Piacentini, F | |
| Achievements and unmet needs in the management of advanced ovarian cancer | 1-gen-2010 | Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco | |
| ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER | 1-gen-2010 | Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V. | |
| Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study | 1-gen-2021 | Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V. | |
| Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting | 1-gen-2023 | D'Onofrio, Raffaella; Omarini, Claudia; Toss, Angela; Sperduti, Isabella; Piacentini, Federico; Barbolini, Monica; Cortesi, Laura; Barbieri, Elena; Pettorelli, Elisa; Chiavelli, Chiara; Dominici, Massimo; Moscetti, Luca | |
| Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis | 1-gen-2021 | D'Onofrio, R.; Piacentini, F.; Barbolini, M.; Isca, C.; Nasso, C.; Caggia, F.; Dominici, M.; Moscetti, L.; Omarini, C. | |
| Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial | 1-gen-2015 | Piacentini, Federico | |
| Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer | 1-gen-2010 | Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco | |
| Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. | 1-gen-2019 | Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V. | |
| Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature | 1-gen-2022 | Tornincasa, Antonio; Canino, Fabio; Trudu, Lucia; Barbolini, Monica; Moscetti, Luca; Omarini, Claudia; Dominici, Massimo; Piacentini, Federico |